Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 420

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 420
---
 150,000,000 SHARES. THE APPROVAL OF EACH OF PROPOSAL NOS. 1, 4 AND 5 IS REQUIRED TO CONSUMMATE THE MERGER.**

#### 241
TABLE OF CONTENTS

<div align='center'>**PROPOSAL NO. 6 ADVISORY, NON-BINDING VOTE ON MERGER-RELATED EXECUTIVE COMPENSATION ARRANGEMENTS**</div>

Section 14A of the Exchange Act, which was enacted as part of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, requires that Cara provide stockholders with the opportunity to vote to approve, on non-binding, advisory basis, the payment of certain compensation that will or may become payable by Cara to its named executive officers in connection with the Merger, as disclosed in the section titled “ The Merger — Interests of the Cara Directors and Executive Officers in the Merger — Golden Parachute Compensation. ”

Cara is asking stockholders to indicate their approval of the compensation that will or may become payable by Cara to its named executive officers in connection with the Merger. These payments are set forth in the section titled “ The Merger — Interests of the Cara Directors and Executive Officers in the Merger — Golden Parachute Compensation, ” and the accompanying footnotes. In general, the employment agreements, equity awards and other arrangements pursuant to which these compensation payments may be made have previously formed a part of Cara’s overall compensation program for its named executive officers and previously have been disclosed to stockholders as part of Cara’s annual proxy statements or its other reports filed with the SEC. These historical employment agreements, equity awards and other arrangements were adopted and approved by the compensation committee of the Cara Board, which is composed solely of non-management directors, and are believed to be reasonable and in line with marketplace norms.

Accordingly, Cara is seeking approval of the following resolution at the Cara special meeting:

“RESOLVED, that the stockholders of Cara Therapeutics, Inc. approve, on a nonbinding, advisory basis, the compensation that will or may become payable by Cara to its named executive officers that is based on or otherwise relates to the merger as disclosed pursuant to Item 402(t) of Regulation S-K in the section titled “ The Merger — Interests of the Cara Directors and Executive Officers in the Merger — Golden Parachute Compensation. ”

Stockholders of Cara should note that this proposal is not a condition to the closing of the Merger